Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
29 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Pharis Biotec GmbH - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Pharis Biotec GmbH - Product Pipeline Review - 2014', provides an overview of the Pharis Biotec GmbH's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Pharis Biotec GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Pharis Biotec GmbH including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Pharis Biotec GmbH's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Pharis Biotec GmbH's pipeline products Reasons to buy - Evaluate Pharis Biotec GmbH's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Pharis Biotec GmbH in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Pharis Biotec GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Pharis Biotec GmbH and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharis Biotec GmbH - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Pharis Biotec GmbH and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Pharis Biotec GmbH Snapshot 5 Pharis Biotec GmbH Overview 5 Key Information 5 Key Facts 5 Pharis Biotec GmbH - Research and Development Overview 6 Key Therapeutic Areas 6 Pharis Biotec GmbH - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Out-Licensed Products 10 Out-Licensed Products/Combination Treatment Modalities 11 Pharis Biotec GmbH - Pipeline Products Glance 12 Pharis Biotec GmbH - Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 Pharis Biotec GmbH - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Pharis Biotec GmbH - Drug Profiles 15 VIR-576 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 hPTH-1-37 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 ALB-408 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 CCL-14 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 LEKTI-6 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Peptide for Herpes Simplex Infections 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Peptide for Metabolic Diseases 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 VIR-353 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Pharis Biotec GmbH - Pipeline Analysis 23 Pharis Biotec GmbH - Pipeline Products by Target 23 Pharis Biotec GmbH - Pipeline Products by Route of Administration 24 Pharis Biotec GmbH - Pipeline Products by Molecule Type 25 Pharis Biotec GmbH - Pipeline Products by Mechanism of Action 26 Pharis Biotec GmbH - Locations And Subsidiaries 27 Head Office 27 Other Locations & Subsidiaries 27 Appendix 28 Methodology 28 Coverage 28 Secondary Research 28 Primary Research 28 Expert Panel Validation 28 Contact Us 29 Disclaimer 29
List of Tables Pharis Biotec GmbH, Key Information 5 Pharis Biotec GmbH, Key Facts 5 Pharis Biotec GmbH - Pipeline by Indication, 2014 7 Pharis Biotec GmbH - Pipeline by Stage of Development, 2014 8 Pharis Biotec GmbH - Monotherapy Products in Pipeline, 2014 9 Pharis Biotec GmbH - Out-Licensed Products in Pipeline, 2014 10 Pharis Biotec GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2014 11 Pharis Biotec GmbH - Phase I, 2014 12 Pharis Biotec GmbH - Preclinical, 2014 13 Pharis Biotec GmbH - Discovery, 2014 14 Pharis Biotec GmbH - Pipeline by Target, 2014 23 Pharis Biotec GmbH - Pipeline by Route of Administration, 2014 24 Pharis Biotec GmbH - Pipeline by Molecule Type, 2014 25 Pharis Biotec GmbH - Pipeline Products by Mechanism of Action, 2014 26 Pharis Biotec GmbH, Subsidiaries 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.